Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy and Safety of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Subjects With Congenital Fibrinogen Deficiency

Trial Profile

Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy and Safety of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Subjects With Congenital Fibrinogen Deficiency

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Fibrinogen (Primary)
  • Indications Afibrinogenaemia; Haemorrhage
  • Focus Registrational; Therapeutic Use
  • Sponsors Octapharma
  • Most Recent Events

    • 12 Apr 2018 Planned End Date changed from 1 Oct 2019 to 1 May 2018.
    • 12 Apr 2018 Planned primary completion date changed from 1 Oct 2019 to 1 May 2018.
    • 05 Apr 2018 Last checked against Iranian Registry of Clinical Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top